Diagnostic tests for Lyme disease could soon get major improvements as seven innovative research and development groups prepare their new methods for review by the Food and Drug Administration.
If the FDA deems them ready for the market, these new tests could significantly improve doctors’ ability to detect early, as well as latent, chronic stages. Borrelia burgdorferi infections, along with other pathogens related to pathogens.
A new crop of trials are the first fruits to emerge from it LymeX Innovation Accelerator– the largest public-private effort of its kind targeting Lyme, has awarded more than $10 million in prize money to research groups in biotechnology and/or academia able to develop clinically validated, FDA-approved testing methods.
First established in 2020 during Trump’s first term, the LymeX Accelerator is a collaboration between the US Department of Health and Human Services and biotech and academic research groups. HHS’ model of success KidneyX Acceleratorit is a private and public “month” focused on developing new and better diagnostics and treatments for Lyme and other tick-borne disorders.
Funding of monetary rewards from the account Stephen and Alexandra Cohen Foundationis a broad-based charity and the largest private funder of Lyme and infectious disease research. Stephen Cohen – a hedge fund manager with a personal fortune of more than $21 billion – and his wife, Alex, launched LymeX after years of trying to deal with Lyme.
HHS’s monetary investment in the LymeX Accelerator is minimal—a nominal $5 million to support logistics and implementation—and there are no dedicated federal funds on the horizon. But the administration has committed various departments under its auspices to equip the Accelerator with AI screening tools, data-sharing capabilities, and public education platforms.
Renewing the LymeX partnership is a cornerstone New HHS initiative to fight chronic Lyme diseasein detail at the round table held in December last year. The administration has prioritized addressing major gaps in diagnostic testing, clinical care for many Lyme patients, and a general dismissal of the reality of chronic Lyme disease that has characterized federal policy as well as insurance reimbursement guidelines for decades.
The root of the problem is that traditional serological testing often misses early-stage infections because it can take up to 4 weeks for the immune system to develop antibodies. Borrelia burgdorferi. Although it is accurate in detecting later stages of infection, the standard double-layer antibody test cannot distinguish between currently active and inactive infections in the past, and it becomes less accurate over time. as the pathogen sequesters itself in collagen-rich tissues of the body.
Conventional logic dictates: “No error, no disease, no need for treatment.” After decades of antibiotic overuse, some degree of discretion is perfectly reasonable. But due to the limitations of current testing methods, many who need treatment do not receive it.
And if the doctor does not think to order a test based on PCR to determine it
B. burgdorferi in synovial fluid, or tests for other joint pathogens, such as Borrelia, Bartonella, Anaplasma and Babesia, these problems are usually not detected, although they can cause significant dysfunction in many organ systems.
Therefore, patients who have long-lasting, complex symptoms that develop or persist months or even years after a tick bite are told that they do not have Lyme, or that the infection has resolved if they do. They are not cured or improved.
Seven 7 R&D teams near the FDA’s finish line are advancing new blood and urine detection methods with new tests. B. burgdorferi in all stages of infection, including latent and chronic stages.
BlueArc Biosciences Inc: This biotech startup has developed an ultra-sensitive blood test for direct detection B. burgdorferi at the very onset of symptoms, thus eliminating the usual 2-4 week seroconversion period between primary infection and the development of antibodies detectable by standard methods. The BlueArc method uses standard laboratory equipment, but previously unrecognized markers that directly detect the presence of the spirochete, instead of waiting for the immune system to respond to it.
Drexel University College of Medicine: The Drexel team led by Mary Ann Communale has created a new small-volume serum assay that uses glycan biomarkers to detect active B. burgdorferi infections. The test can help in early diagnosis as well as monitoring treatment.
HelixBind Inc: This Boston-area biotech company has developed a completely new technology platform to detect Borrelia DNA directly from human blood. HelixBind assays use RaPID/LD for rapid amplification of genetic material. This technology has been successfully applied to detect tuberculosis, respiratory syncytial virus and other respiratory infections. It can return very sensitive results, often within 15-30 minutes.
Galaxy Diagnosis: Galaxy, located in North Carolina’s Research Triangle Park, focuses on sensitive urine antigen tests to detect Borrelia, as well as Bartonella and Babesia—tick “hidden pathogens” that easily evade standard serum antigen tests. Galaxy tests detect the pathogens themselves, not the body’s immune response to them.
Northwestern University Feinberg School of Medicine: A Northwestern research team led by Brandon Jutras, Ph.D., has combined a monoclonal antibody test with immuno-PCR-based methods that can rapidly detect the presence of Borrelia-specific peptidoglycan in both blood and urine. This peptidoglycan, a strong inducer of chronic inflammation, can also be found in the synovial fluid after the initial stage of infection.
Massachusetts General Hospital: The popular generic has long been at the forefront of Lyme research. In fact, Allen Steer, who now directs the hospital’s Lyme arthritis program, is credited with discovering and describing Lyme disease in 1976. Today, international researchers John Branda and Jacob Lemieux have used genome sequencing techniques to detect low levels of nucleic acid chains in the blood. Their method dilutes human background material from serum samples, amplifying genetic signals that indicate the presence of a pathogen.
GNOMX Corp: GNOMX is based in New York, which offers AI in the evaluation of epigenetic signals B. burgdorferi infection Although it is an indirect method in that it does not directly identify the pathogen, it uses biologically distinct indicators and has proven sensitive in early trials with greater than 90% accuracy in detecting Lyme at an early stage.
It remains to be seen which of these new methods will win the FDA approval. But the growing growth of research in the field of Lyme disease is certainly a good sign that the stasis that has characterized the clinical diagnosis and treatment of Lyme will be shaken in the near future.
DOWN
